Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI-0301 Gene-Transduced Donor Lymphocyte Infusion After Allogeneic HSCT
jRCT2080220900Phase 1
- Sponsor
- Takara Bio Inc.
- Start
- Oct 2009
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TBI-0301 in hematopoietic malignancies, leukemia, lymphoma and 1 more, sponsored by Takara Bio Inc. Primary endpoints: Primary safety endpoints and Primary efficacy endpoints.
02
Drugs
TBI-0301
03
Conditions
hematopoietic malignanciesleukemialymphomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2080220900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220900.